Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is one of the largest biopharmaceutical companies globally, headquartered in North Chicago, Illinois. The company specializes in immunology, oncology, neuroscience, aesthetics, and eye care therapeutics, making its news coverage particularly valuable for tracking developments across multiple billion-dollar healthcare markets.
AbbVie news reflects the company diverse therapeutic focus. Immunology updates often include clinical trial results for next-generation autoimmune disease treatments, including JAK inhibitors and other novel mechanisms targeting conditions like rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. These announcements can signal shifts in competitive dynamics within the autoimmune drug market.
The oncology division generates news around FDA approvals, clinical trial data, and pipeline developments for cancer therapies. AbbVie cancer portfolio includes treatments for hematologic malignancies such as chronic lymphocytic leukemia and multiple myeloma, with ongoing expansion into solid tumor indications. Drug approval timelines and efficacy data from late-stage trials represent key news catalysts.
Neuroscience news covers developments in migraine treatment and Parkinson disease therapies, including CGRP-targeting drugs and advanced delivery systems. The Allergan Aesthetics division, acquired through AbbVie purchase of Allergan, generates news around cosmetic treatment innovations, market expansion, and competitive positioning in the medical aesthetics space.
Quarterly earnings reports provide insight into segment performance across immunology, oncology, and aesthetics divisions. Strategic announcements regarding acquisitions, licensing deals, and pipeline partnerships appear regularly as AbbVie pursues external innovation to supplement internal research. Bookmark this page to track regulatory decisions, clinical milestones, and strategic moves from one of biopharma largest players.
AbbVie announced 100-week results from KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI (risankizumab) in adults with active psoriatic arthritis. Over 50% of patients achieved a 90% reduction in psoriasis severity (PASI 90), with similar joint symptom improvement (ACR20) as at week 52. The treatment maintained long-term efficacy, with no new safety signals observed. Serious treatment-emergent adverse events were low, with a rate of 7.6 E/100PY in KEEPsAKE 1. These findings were presented at the 31st EADV Congress, highlighting SKYRIZI's potential as a long-term treatment option.
AbbVie Inc. (NYSE: ABBV) has declared a quarterly cash dividend of $1.41 per share, payable on November 15, 2022, to shareholders of record by October 14, 2022. Since its inception in 2013, AbbVie has increased its dividend by over 250%. The company is a member of the S&P Dividend Aristocrats Index, which includes firms that have consistently raised dividends for at least 25 consecutive years.
AbbVie's MEASURE-AD study, spanning three years and 28 countries, highlights the significant clinical, psychosocial, and economic burdens faced by patients with moderate to severe atopic dermatitis, particularly those not on systemic therapy. Results presented at the EADV Congress indicate that these patients experience higher disease severity scores and lower quality of life, emphasizing the need for improved treatment options. The analysis shows that only half of eligible patients receive systemic therapy, revealing potential undertreatment in this population.
AbbVie announced new data from its migraine portfolio at the Migraine Trust International Symposium 2022 in London, from September 8-11. The presentation will include results from the Phase 3 PROGRESS trial for atogepant, aimed at preventing chronic migraine, alongside additional studies on onabotulinumtoxinA and ubrogepant. The company will highlight its commitment to addressing the unmet needs of migraine patients. A medical symposium titled "Evolving Faces of Migraine" will also take place during the event.
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 9:35 a.m. Central time. Key speakers include Rob Michael, Jeff Stewart, and Neil Gallagher. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version accessible later in the day.
AbbVie aims to deliver innovative medicines across various fields like immunology, oncology, and neuroscience, enhancing patient care and addressing health challenges.
On August 31, 2022, Allergan Aesthetics, part of AbbVie (NYSE: ABBV), launched the SkinMedica® Firm & Tone Lotion for Body. This innovative product is designed to combat visible signs of body skin aging, such as crepiness and uneven texture. Clinically proven to improve skin firmness and tone, it features a blend of ingredients like Green Microalgae and Shitake Mushroom Extracts. Dermatologists endorse its use both as a standalone product and post body contouring. Priced at $165 USD, it aims to cater to the unique skincare needs of body skin.
Allergan Aesthetics, part of AbbVie, released 'The Future of Aesthetics' report, highlighting trends in the medical aesthetics industry, driven by changing consumer attitudes. The North American medical aesthetic market is expected to grow over 10% annually through 2026. The report suggests an increasing demand for minimally invasive procedures, with predictions of 23 million dermal fillers and 14.6 million body procedures by 2025. The research emphasizes the need for practitioners to adapt to a diverse and knowledgeable patient base.
AbbVie announced the presentation of 23 abstracts at the 31st European Academy of Dermatology and Venereology Congress, focusing on SKYRIZI® (risankizumab) for treating moderate to severe psoriasis and active psoriatic arthritis. Key presentations include long-term efficacy and safety data from ongoing clinical trials and real-world studies. The research highlights AbbVie's commitment to understanding immune-mediated skin diseases, showcasing innovative treatment options in areas with limited alternatives.
The FDA has approved IMBRUVICA (ibrutinib) for pediatric patients aged one year and older suffering from chronic graft-versus-host disease (cGVHD) after failure of earlier systemic therapies. This marks AbbVie's first pediatric indication for IMBRUVICA and provides a novel treatment for children under 12 affected by cGVHD, a condition following stem cell transplants. The approval is based on positive results from the iMAGINE Phase 1/2 trial, showing a 60% overall response rate in participants. The recommended dosage varies by age, with an oral suspension formulation available for easier administration.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
